While our results suggest that plasma NfL may be used as a minimally invasive and easily obtainable biomarker of cognitive decline in dementia-free individuals from the general population, further study is needed to determine if the predictive value of NfL is sufficient to serve, for example, treatment selection or inclusion in clinical trials. This evidence concerns the gene NEFL and Mental deterioration.